Federal Circuit Upholds Ruling in Favor of Novel Laboratories, Inc. in Sleep Aid Patent Case

January 11, 2016

The United States Court of Appeals for the Federal Circuit has upheld a New Jersey district court’s ruling in favor of Robins Kaplan client Novel Laboratories, Inc., finding that three of Purdue Pharmaceutical Products LP’s patents for the sleep aid Intermezzo are invalid because they were obvious.

Novel Laboratories, along with Actavis Elizabeth LLC, Dr. Reddy’s Labs., Ltd., and others, had been sued by Purdue over plans to market their own generic versions of Intermezzo®, a sleep medication designed to aid people who wake up in the middle of the night and cannot fall back to sleep. In March 2015, U.S. District Judge Jose L. Linares had ruled in favor of the generic drug companies after a 10-day bench trial, finding that Purdue’s patents are invalid for obviousness.

Purdue and co-appellant Transcept Pharmaceuticals Inc. appealed the validity of one of the patents, and argued that the patent was for a different dosage of sleep medication than other insomnia drugs on the market at the time. However, with last Friday’s summary affirmance, the Federal Circuit has upheld the district court’s ruling that Purdue’s patents were invalid as obvious.

Jake Holdreith, leader of the firm’s Health and Life Sciences Industry Group, argued on behalf of all defendants. Holdreith, along with Jeff Hovden, Oren Langer, and Miles Finn, represented Novel Laboratories. The case is Purdue Pharmaceutical v. Actavis Elizabeth LLC, case number 15-1659, in the U.S. Court of Appeals for the Federal Circuit.

See here for Law360’s coverage of the decision.

Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Oren D. Langer


Managing Partner, New York Office

Related Publications

First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top